Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial
By Julie Steenhuysen and Christy Santhosh CHICAGO, Aug 19 (Reuters) - Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread in a late-stage trial when combined with Keytruda, sending the biotech's shares surging 90% in premarket trading.